Scholarlink

<p>The use of TRECs/KRECs in allogeneic HSCT (alloHSCT) has been limited by a lack of standard technical platforms to allow comparison and validation of results between centers. We quantified absolute TRECs/KRECs on sequential samples collected prospectively (pre-transplant, 1, 3, 6 and 12 months post-transplant) in 374 alloHSCT for hematological malignancies using LightCycler 480/TREC-KREC- ACTB (Roche Diagnostics). Following prompt decrease after transplant, KRECs recover as soon as 3 months posttransplant, while TRECs recovery takes up to 1 year (<i>p</i> &lt; 0.001). KRECs do not associate with outcomes. However, higher pre-transplant TRECs strongly associate with reduced non-relapse mortality (NRM) and increased overall survival (OS), and remain independent in multivariate analysis (HR 0.37, <i>p</i> = 0.001, and HR 0.51, <i>p</i> &lt; 0.001, respectively). In addition, faster TRECs recovery measured sequentially at 1, 3, 6 and 12 months after alloHSCT associates with better OS. Furthermore, landmark analyses showed that early survivors with higher TRECs levels at 6 and 12 months after alloHSCT had significantly better subsequent long-term survival, independent from graft-versus-host disease (GVHD) and other clinical factors in multivariate analysis (HR 0.33, <i>p</i> = 0.016 and HR 0.13, <i>p</i> &lt; 0.001, respectively). TRECs levels pre-transplant and at 6 and 12 months post-transplant provide novel biomarker measurable data that associate with alloHSCT long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sequential quantification of T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) and overall survival after allogeneic HSCT

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月29日

查看全文
  • Carlos de Miguel,
  • Ferran Briansó,
  • Rosalía Alonso,
  • Guiomar Bautista,
  • Luis Espinosa,
  • Carlos Manchado-Perdiguero,
  • María E. Martínez-Muñoz,
  • Lucía Núñez,
  • Isabel Salcedo,
  • Ali Sánchez-Peral,
  • Rafael F. Duarte

摘要

The use of TRECs/KRECs in allogeneic HSCT (alloHSCT) has been limited by a lack of standard technical platforms to allow comparison and validation of results between centers. We quantified absolute TRECs/KRECs on sequential samples collected prospectively (pre-transplant, 1, 3, 6 and 12 months post-transplant) in 374 alloHSCT for hematological malignancies using LightCycler 480/TREC-KREC- ACTB (Roche Diagnostics). Following prompt decrease after transplant, KRECs recover as soon as 3 months posttransplant, while TRECs recovery takes up to 1 year (p < 0.001). KRECs do not associate with outcomes. However, higher pre-transplant TRECs strongly associate with reduced non-relapse mortality (NRM) and increased overall survival (OS), and remain independent in multivariate analysis (HR 0.37, p = 0.001, and HR 0.51, p < 0.001, respectively). In addition, faster TRECs recovery measured sequentially at 1, 3, 6 and 12 months after alloHSCT associates with better OS. Furthermore, landmark analyses showed that early survivors with higher TRECs levels at 6 and 12 months after alloHSCT had significantly better subsequent long-term survival, independent from graft-versus-host disease (GVHD) and other clinical factors in multivariate analysis (HR 0.33, p = 0.016 and HR 0.13, p < 0.001, respectively). TRECs levels pre-transplant and at 6 and 12 months post-transplant provide novel biomarker measurable data that associate with alloHSCT long-term outcomes.